

ORIGINAL ARTICLE**ROLE OF LASER PHOTOCOAGULATION VERSUS INTRAVITREAL TRIAMCINOLONE ACETONIDE IN ANGIOGRAPHIC MACULAR EDEMA IN DIABETES MELLITUS****Aggarwal Somesh VP¹, Shah Sonali N², Bharwada Rekha M³, Billore Puja S⁴**¹Associate Professor, ²Assistant Professor, ³Professor, ⁴Tutor, Vitreo Retina Unit, M . & J Western regional Institute Of Ophthalmology, Civil Hospital campus, Ahmedabad**Correspondence**

Dr. Somesh Aggarwal, Email: Dr.somesh@yahoo.com

ABSTRACT**Aims:** To compare the effect of laser photocoagulation and intravitreal triamcelone acetonide in the treatment of diabetic macular edema**Material and Methods:** During the period of one year 100 patients having diabetic macular edema were enrolled in the project. Fluorescein angiography was carried out in all patients to confirm the diagnosis of macular edema. Patients were randomly assigned into two groups. One group was treated with laser photocoagulation and other group was given intravitreal triamcinolone.**Observations:** 82 % of patients were of type 2 diabetes while 18 % had type 1 diabetes. 40 % patients had the disease for more than 15 years. 48 % patients had diffuse macular edema on fluorescein angiography. 38 % showed a focal pattern of edema and 14% showed a mixed pattern.

At three months patients receiving triamcinolone had better visual acuity compared to laser photocoagulation. However these findings were reversed by 12 months and laser photocoagulation remained superior to triamcinolone at the end of 1 year of follow up.

Discussion: A similar study conducted by DRCR compared laser photocoagulation to intravitreal triamcinolone for treatment of diabetic macular edema. At four months, patients receiving intravitreal triamcinolone had better visual acuity compared to laser photocoagulation. These findings were reversed by 16 months, and laser photocoagulation remained superior to triamcinolone at three-year follow-up.**Conclusion:** Our study showed that although intravitreal triamcinolone was successful in improving visual acuity in patients at the end of 3 months the effect was transient and in long term laser photocoagulation was more effective.**Key Words:** Diabetes Mellitus, Macular Edema, Photocoagulation**INTRODUCTION**

Macular edema or retinal thickening is an important manifestation of DR and the most common cause of moderate visual loss.

ETDRS demonstrated that laser treatment prevented moderate visual loss (loss of 15 letters or three lines on the standard ETDRS visual acuity chart) in 24% eyes, compared to 12% in untreated controls, at 3 years.¹

Although laser photocoagulation has been demonstrated to be beneficial in reducing further vision loss, vision that has already been decreased by macular edema usually does not improve. Identification of a

treatment that could improve vision is desirable and of public health importance.

Prospective case series have demonstrated improvement of macular edema and visual acuity in eyes with refractory macular edema treated with intravitreal triamcinolone acetonide. (IVTA). The role of steroids on macular edema is based on their inhibition of inflammatory inhibitors, stabilization of blood-retinal barrier and inhibition of VEGF expression.

Studies evaluating the role of intravitreal triamcinolone acetonide have small sample size with relatively short follow up. Longer term evaluation is needed. The main adverse effects of raised intraocular pressure and

increasing cataract formation have not been fully evaluated.

The aim of our study was to determine whether intravitreal triamcinolone acetonide injections produce greater benefit, with an acceptable safety profile, than macular laser photocoagulation in the treatment of diabetic macular edema

MATERIALS AND METHODS

Total 100 eyes of 100 patients attending the OPD at M & J Institute Of Ophthalmology and having Diabetic macular edema were enrolled in this project.

Detailed inclusion and exclusion criteria were followed. Following patients were excluded from this study –

- Presence of NO perception or projection of light.
- Presence of any other retinal, macular or optic nerve pathology other than diabetic macular edema likely to affect visual outcome.
- Uncontrolled intraocular pressure or eyes with preexisting glaucoma
- Active inflammation in anterior segment.
- Patients with advanced cataractous changes, complicated pseudophakia and corneal opacities making indirect ophthalmoscopy impossible.
- Patients with advanced renal disease making fluorescein angiography impossible.
- Patients with previous history of intervention in form of laser or intravitreal injections.
- Patients with macular ischemia on FFA.

Written informed consent was taken before recruiting the patients for the study. Base line examination like visual acuity, detailed anterior segment examination, slit lamp biomicroscopy and Fundus fluorescein angiography were done in all patients. Routine blood investigation like FBS, PPBS, Blood Urea and S.Creatinine were done before taking the patient for fluorescein angiography.

Any history of adverse drug reactions was ruled out before doing angiography. Macular edema was classified angiographically as focal and diffuse. Focal edema was defined as fluorescein leakage mainly originating from microaneurysms or intraretinal microvascular abnormalities at the posterior pole on angiography. Diffuse macular edema was defined by a general breakdown in the blood retinal barrier with diffuse fluorescein leakage in central macular area. In cystoid macular edema associated with diabetes mellitus late phase FFA showed dye pooling in the central fovea region in petalloid pattern. Macular ischemia was defined as enlargement of foveal avascular zone or any disruption of the peri-foveal capillary net best observed during early phase of FFA.

The patients were randomly divided into two groups. One group was given intravitreal triamcinolone acetonide (4 mg/0.1 ml) in one eye. The intravitreal injection was performed under topical anesthesia with

proparacaine eye drops. A lid speculum was used to keep the eyelashes away from the conjunctiva. Povidone iodine 5% eye drops and antibiotic eye drops were instilled in the conjunctiva every five minutes for three times. The injection of triamcinolone acetonide 4 mg in 0.1 mL was performed through a 26-ga. needle in the inferotemporal pars plana 4 mm posterior to the limbus in phakic eyes and 3.5 mm posterior in pseudophakic eyes. After the injection, indirect ophthalmoscopy fundus examination was used to evaluate the perfusion of the central retinal artery and the intravitreal location of the triamcinolone. The patient was given sitting position for 4 hours and acetazolamide tablets to prevent the rise of intraocular pressure post procedure. IOP was assessed after 4 hours and Fundus was examined to rule out any complication.

The second group was given laser photocoagulation according to modified ETDRS protocol, which involved both direct treatment of microaneurysms and grid laser to areas of thickened retina only. Small laser spot sizes 50-100 micron spaced 50-100 micron apart were placed using low power setting avoiding the foveal avascular zone.

Follow up visits were scheduled one week, one month post procedure and every two monthly thereafter.

Visual acuity testing, iop monitoring, cataract assessment, slitlamp biomicroscopy were done at each visit. Fluorescein angiography was done at 3, 9 and 12 months to assess the amount of regression of edema and look for recurrence.

The main outcome measures were visual acuity and macular edema on angiography. The complications on follow up were also noted. Retreatment assessment was done every 4 months and patients were treated as required.




Fig 1: Diffuse Diabetic Edema on FFA




Fig 2: Cystoid Macular Edema



Fig 3: Focal Macular Edema on FFA

OBSERVATIONS

Clinical details of patients

Characteristics of patients are shown as shown in table one and two.

The patients registered in the project were in the age range of 40 to 76 years. 82 % of patients were of type 2 diabetes while 18 % had type I diabetes. 40 % patients had the disease for more than 15 years. 48 % patients had diffuse macular edema on fluorescein angiography. 38 % showed a focal pattern of edema and 14% showed a mixed pattern.

The main outcome measures were visual acuity and macular edema on angiography. At three months patients receiving triamcinolone had better visual acuity compared to laser photocoagulation. 50% of patients treated with triamcinolone had gain in visual acuity of more than 3 lines on SNELLEN’s chart as compared to 20% of patients treated with laser photocoagulation. the difference was found to be statistically significant at 99% confidence limits.

Table 1: Characteristic of Patient in both Groups

	Group 1* (n=50)	Group 2# (n=50)	Total
Gender			
Female	18	19	37
Male	32	31	63
Age			
40-50	10	14	24
51-60	20	17	37
61-70	8	15	23
71 and Above	12	4	16
Type of Diabetes			
Type 1	10	8	18
Type 2	40	42	82
Visual Acuity			
6/18 to 6/60	19	11	30
6/60 to 3/60	25	31	56
3/60 to hm	6	8	14
Duration of diabetes			
5-10 yrs	6	5	11
10-15 yrs	21	28	49
> 15 yrs	23	17	40

*Group 1 = Focal/Grid Laser Photocoagulation

#Group 2 = 4 mg Intravitreal Triamcinolone Acetonide

Table 2: Type of Macular Edema and Change in Visual Acuity after Various Time Intervals

	Gr 1* (n=50)	Gr 2# (n=50)	Total
Type of Macular Edema			
Focal	18	20	38
Diffuse	24	24	48
Mixed	8	6	14
Gain/Loss in Visual Acuity From Baseline to 3 Months			
> 3 Line Gain	10	25	35
2 to 3 Lines Gain	24	17	41
0 to 1 Line Gain	15	4	19
Loss of 1 Line	1	2	3
2 to 3 Lines Loss	0	1	1
> 3 Lines Loss	0	1	1
From Baseline to 12 Months			
> 3 Line Gain	28	12	40
2 - 3 Lines Gain	14	10	24
0 - 1 Line Gain	4	16	20
Loss of 1 Line	1	5	6
2 - 3 Line Loss	2	4	6
> 3 Lines Loss	1	3	4

*Gr 1 = Focal/Grid Laser Photocoagulation

#Gr 2 = 4 mg Intravitreal Triamcinolone Acetonide

However these findings were reversed by 12 months and laser photocoagulation remained superior to triamcinolone at the end of 1 year of follow up. 46% of patients in laser treated group gained 3 or more lines of vision at the end of one year as compared to 24 % patients in the triamcinolone group. The difference was statistically significant at 95% confidence limits. Conversely 2 % of patients treated with laser lost 3 or

more lines on follow up as compared to 6% of patients treated with triamcinolone.

The findings on angiography paralleled those of visual acuity revealed that 16% of eyes treated with triamcinolone had intraocular pressure > 21 mm hg and were put on topical glaucoma medication. 8 % of eyes had rapid progression of cataract after triamcinolone. There were no other complications like vitreous hemorrhage, retinal detachment and endophthalmitis in the triamcinolone group.

DISCUSSION

Diabetic retinopathy represents the sixth leading cause of blindness in the world. Diabetic macular edema remains the most frequent cause of vision loss among the diabetic population and is particularly prevalent among Insulin dependent type 2 diabetics.

Traditional concepts of the pathophysiology of macular edema have focused on hyperglycemic damage to vascular endothelium, thickening of the basement membrane and death of retinal pericytes contributing to breakdown in inner blood- retinal barrier. Ongoing research has identified that leakage of plasma and fluid from the damaged mediators is also influenced by release of soluble vascular and inflammatory mediators including vascular endothelial growth factors (VEGF) and proinflammatory cytokines.

Macular edema is clinically detected by stereoscopic examination techniques. The ETDRS (Early Treatment Diabetic Retinopathy Study) classified macular edema by its severity¹. It was defined as Clinically Significant Macular Edema (CSME) if any of the following features were present: 1) thickening of the retina at or within 500 micron of the centre of macula. 2) Hard exudates at or within 500 micron of the centre of macula if associated with thickening of the adjacent retina. 3) A zone of retinal thickening one disc area or larger any part of which is within one disc diameter of the centre of macula.

Laser photocoagulation- FFA guided laser photocoagulation directly targets leaking microaneurysms (focal) and areas of diffuse retinal thickening or angiographic leakage (grid). Small laser spot sizes 50-100 micron spaced 50-100 micron apart are placed using low power setting avoiding the foveal avascular zone. ETDRS has shown that focal/ grid laser photocoagulation reduced the risk of moderate visual loss by about 50% in eyes with diabetic macular edema. Focal laser reduces hypoxic areas and directly occludes microaneurysms. Grid laser has its effects by thinning the retina, bringing retinal vessels closer to choroidal vessels and permitting the retinal vessels to close by auto regulation.

Corticosteroid therapy for macular edema- prospective case series have demonstrated improvement of macular edema and visual acuity in eyes with refractory macular edema treated with intravitreal triamcinolone acetonide.

(IVTA). The role of steroids on macular edema is based on their inhibition of inflammatory inhibitors, stabilization of blood-retinal barrier and inhibition of VEGF expression. Complications of IVTA include retinal detachment, cataract progression, endophthalmitis, vitreous hemorrhage and raised intraocular pressure.

The aim of our study was to determine whether intravitreal triamcinolone acetonide injections produce greater benefit, with an acceptable safety profile, than macular laser photocoagulation in the treatment of diabetic macular edema.

Our study showed that although intravitreal triamcinolone was successful in improving visual acuity in patients at the end of 3 months the effect was transient and in long term laser photocoagulation was more effective.

A similar study conducted by DRCR compared laser photocoagulation to intravitreal triamcinolone for treatment of diabetic macular edema. At four months, patients receiving intravitreal triamcinolone had better visual acuity compared to laser photocoagulation. These findings were reversed by 16 months, and laser photocoagulation remained superior to triamcinolone at three-year follow-up..

In their paper, Desatnik et al. report that intravitreal injection of triamcinolone acetonide is effective in reducing foveal thickness² and improves visual acuity in the short term, but that visual acuity returned to pre-injection values and only a moderate reduction in foveal thickness persisted.

Massin et al.³ prospectively evaluated the effect of a single IVTA 4 mg injection in one eye compared to the control fellow eye in 15 patients with bilateral diabetic macular edema unresponsive to laser treatment. There was a significant decrease in macular thickness in favor of the injected eye after 3 months, but that difference was no longer significant after 6 months due to recurrence of macular edema

Jonas et al.⁴ conducted a large prospective comparative study on 166 eyes of 136 patients and reported a significant increase in visual acuity in eyes assigned for IVTA 20–25 mg compared to eyes assigned for laser treatment.

Avitabile et al.⁵ showed better visual acuity outcome and lower central macular thickness in 22 eyes that received IVTA 4 mg compared to 21 eyes that received grid laser treatment.

Patelli and team⁶ reported that IVTA was effective in reducing macular thickness and improving visual acuity in eyes with and without previous laser treatment, but stated that it is not yet clear whether IVTA should be considered as an initial treatment.

A study by Ockrim et al⁷ to determine if repeated intravitreal triamcinolone improves best corrected visual acuity at 1 year compared with conventional laser therapy for persistent diabetic macular oedema did not

show a benefit from intravitreal triamcinolone over conventional laser therapy.

CONCLUSION

To conclude our study showed that although intravitreal triamcinolone was successful in improving visual acuity in patients at the end of 3 months the effect was transient and in long term laser photocoagulation was more effective.

ACRONYMS

IVTA- Intra Vitreal Triamcelone Acetonide
PC – Photocoagulation
DR- Diabetic Retinopathy
DM- Diabetes Mellitus
ETDRS-Early Treatment Diabetic Retinopathy Study
CSME- Clinically Significant Macular Edema
FFA- Fundus Fluorescine Angiography

REFERENCES

1. Early treatment of diabetic retinopathy study research group. Early photocoagulation for diabetic retinopathy. ETDRS report number 9. *ophthalmology* 1991.
2. Desatnik H, Habot-Wilner Z, Alhalel A, Moroz I, Glovinsky J, Moisseiev J. The transient efficacy of a single intravitreal triamcinolone acetonide injection for diabetic macular edema. *IMAJ* 2006;8:383–7.
3. Massin P, Audren F, Haouchine B, et al. Intravitreal triamcinolone acetonide for diffuse diabetic macular edema – preliminary results of a prospective controlled trial. *Ophthalmology* 2004;111: 218–25
4. Jonas JB, Akkoyun I, Kreissig I, Degenring RF. Diffuse diabetic macular oedema treated by intravitreal triamcinolone acetonide: a comparative, non-randomised study. *Br J Ophthalmol* 2005;89:321–6.
5. Avitabile T, Longo A, Reibaldi A. Intravitreal triamcinolone compared with macular laser grid photocoagulation for the treatment of cystoid macular edema. *Am J Ophthalmol* 2005;140:695–702.
6. Patelli F, Fasolino G, Radice P, et al. Time course of changes in retinal thickness and visual acuity after intravitreal triamcinolone acetonide for diffuse diabetic macular edema with and without previous macular laser treatment. *Retina* 2005;25:840–5.
7. Z K Ockrim, S Sivaprasad, S Falk, S Roghani, C Bunce, Z Gregor, P Hykin. Intravitreal triamcinolone versus laser photocoagulation for persistent diabetic macular oedema. *Br J Ophthalmol* 2008;92:795-79.